Vienna Insurance Group’s Nurix Therapeutics NRIX Stock Holding History

Vienna Insurance Group’s Portfolio NRIX Stock Details NRIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.06M	Hold	85,000	–	–	0.54%	24
2026 Q1	$1.32M	Hold	85,000	–	–	0.5%	25
2025 Q4	$1.61M	Hold	85,000	–	–	0.79%	23
2025 Q3	$785K	Hold	85,000	–	–	0.46%	23
2025 Q2	$968K	Hold	85,000	–	–	0.61%	24
2025 Q1	$1.01M	Hold	85,000	–	–	0.55%	78
2024 Q4	$1.6M	Hold	85,000	–	–	0.93%	20
2024 Q3	$1.91M	Hold	85,000	–	–	0.81%	26
2024 Q2	$1.77M	Hold	85,000	–	–	0.69%	29
2024 Q1	$1.25M	Hold	85,000	–	–	0.49%	86
2023 Q4	$877K	Hold	85,000	–	–	0.4%	90
2023 Q3	$668K	Hold	85,000	–	–	0.3%	90
2023 Q2	$849K	Hold	85,000	–	–	0.39%	87
2023 Q1	$755K	Buy	+85,000	New	+$886K	0.44%	53

Other funds holding NRIX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vienna Insurance Group's NRIX Position: Q2 2026 in Review

Vienna Insurance Group held its Nurix Therapeutics (NRIX) position steady in Q2 2026 at 85,000 shares worth $2.06M. The position accounts for 0.54% of the portfolio, ranked #24.

Vienna Insurance Group first reported a position in NRIX in Q1 2023 and has held it in 14 quarters since. 211 funds tracked by Wall St. Rank hold NRIX as of Q2 2026.

Vienna Insurance Group held 85,000 shares of Nurix Therapeutics worth $2.06M as of Q2 2026.
Vienna Insurance Group left its Nurix Therapeutics share count unchanged in Q2 2026.
Nurix Therapeutics made up 0.54% of Vienna Insurance Group's portfolio in Q2 2026, its #24 holding.
Vienna Insurance Group first reported a position in Nurix Therapeutics in Q1 2023 and has held it in 14 quarters since.
211 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q2 2026.

Based on Vienna Insurance Group's 13F filing for Q2 2026, filed 30 Jul 2026.